Pharma Faces: Demet Russ, Janssen Turkey
After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to…
The KU Drug Research Center was founded as a centralized facility and core staff, to help collaborators translate basic science into drug discovery programs and has embraced a two-fold strategy in creating an environment for the drug discovery and development:
KU Drug Research Center will combine computational and experimental methods to elucidate, design, validate and apply new pharmacological concepts and strategies to the development and use of therapeutics and diagnostics. KU Drug Research Center will provide an integrated “systems” approach assisted by high-throughput screening techniques to elucidate drug mechanisms of action during discovery, target identification and in clinical trials. Such an endeavor will incorporate the ongoing research for the design and synthesis of novel, drug-like chemical scaffolds, and biologics to address the therapeutic needs. In addition, computational chemistry and molecular biophysics studies to predict and to define target proteins, druggable sites, potential binding affinities will be among the major activities of the center.
The KU Drug Research Center will accept collaborative projects in any therapeutic area where the collaborator has a significant interest and commitment to the program, while focusing internal efforts on cancer, stem cell research, neuroscience and emerging infectious diseases. There is a major commitment to the use of experimental disease models, as well as human-derived cell/engineered tissue models early in the discovery process.
Contact Details
Burak Erman
Professor
Department of Chemical and Biological Engineering
College of Engineering
Koç University
Rumelifeneri Yolu, 34450 Sariyer, Istanbul Turkey
Phone: +90 (212) 338-1704
Fax : +90 (212) 338-1548
Berman@ku.edu.tr
http://home.ku.edu.tr/~iam/About_Us.html
After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to…
Avinash Potnis of Novartis Turkey discusses potential solutions to the country’s access and pricing dilemma which has raised concerns of system sustainability. Potnis also highlights the strengths of Turkey’s healthcare…
Ingrid Drechsel, head of Bayer’s pharma operations in Turkey and Iran, discusses the complexity of managing two countries under economic pressure and the advantages of Bayer’s longstanding relationship in both…
Menarini’s general manager for Turkey, the Middle East and Africa Uğur Bingöl discusses the Italian company’s restructuring in the region and its desire to replicate its success in Turkey across…
The secretary general for Turkey’s Pharmaceutical Manufacturers Association (IEIS), Savaş Malkoç, highlights their objective of increasing R&D expenditure and Turkey’s big opportunity ahead in biosimilars production. In addition, Malkoç discusses…
Janssen’s Managing Director for Turkey, Demet Russ, discusses her return to the country after 25 years abroad, having worked for Johnson & Johnson in different local, regional and global roles…
As one of the leading pharma companies in Turkey, DEVA is pioneering a new approach to generics in the country. Chairman of the Board and CEO Philipp Haas discusses the…
As COVID-19 began spreading through the world, the race to understand the disease by scientists and doctors took off. After just a few months, it became apparent that people with…
The president of the Turkish Society of Cardiology, Mustafa Kemal Erol, discusses the prevalence of cardiovascular disease, which accounts for over a third of deaths in Turkey, the improvements made…
AmCham Turkey’s executive director, Asli Özelli, examines the impact of US companies on the Turkish economy with over USD 50 billion in investment, their help during the pandemic, the chamber’s…
Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials,…
Turkey’s former Minister of Health, Bülent Akarcali, outlines the country’s healthcare system evolution over the past decades, comparing the improvements to the difference between a Ford Model T to a…
See our Cookie Privacy Policy Here
